This finding suggests the dual role of BAP1 somatic mutations—not only as drivers involved in ccRCC initiation but also as enhancers of EMT-related epigenetic regulation, contributing to disease progression. Here, BAP1 is linked to nonpapillary renal cell carcinoma.